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Introduction
Throughout the past decade, nasopharyngeal carcin-
oma (NPC) has been the third most common cancer
and the third most common cause of cancer death in
the male population of Hong Kong. Nasopharyngeal
carcinoma has a tendency to affect the relatively young
population more than most other cancers; the loss of
working life due to NPC is substantial.1
The extent of disease at diagnosis of NPC is the
most important prognostic factor.2-7 While those with
a tumour entirely confined within the nasopharynx
(stage I according to Ho’s classification)8 can achieve
a 5-year actuarial disease-specific survival of 81%, the
median survival for those with distant dissemination
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(stage V) is only 5 months (Fig 1). Unfortunately, the
nasopharynx is not easily visualised and requires the
use of fibroscopy, or a mirror examination with or with-
out general anaesthesia. Moreover, patients usually
have minimal symptoms before the tumour extends
beyond the primary site. This disease is often man-
aged solely by radiotherapists and information about
the disease from general textbooks is scant due to its
rarity in the West. Consequently, doctors from other
specialties (except otolaryngologists) are often un-
familiar with the natural course of NPC. It is not sur-
prising therefore that very few patients present with
Stage I disease.9
The purpose of this study was to review the pre-
senting features of NPC and the detrimental effect of
a delay in presentation on the final outcome.
Subjects and methods
Patient characteristics
We studied 5020 patients with undifferentiated or non-
keratinising carcinoma of the nasopharynx who were
primarily treated at the Queen Elizabeth Hospital dur-
ing 1 January 1976 to 31 December 1985. Excluding
the 252 (5.0%) patients who failed to give a clear his-
tory of symptoms and their duration, the present study
concentrated on the remaining 4768 patients. The male
to female ratio was 2.8 to 1.0, and their ages ranged
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from 10 to 88 years (median, 48 years). Ninety-one
percent of patients had been regularly followed up until
death or the present time of analysis.
Clinical staging
All patients were staged by anterior rhinoscopy, indi-
rect nasopharyngoscopy, and radiography of the chest
and nasopharyngeal regions using the special views
recommended by Ho.10 Computed tomography was
only done in 689 (14.5%) patients, as this method of
investigation was not available until late 1980. Direct
fibroscopy as a method of examination of the upper
airway was gradually implemented after 1982.
Treatment
The general policy was to treat as many patients as
possible with radical radiotherapy. The radiation
techniques and dosage schemes have been described
in detail by Ho.11 Basically, all potential sites of local
infiltration were irradiated to a total dose of 65 Gy
equivalent.
Only 4313 (90.5%) of the patients in the present
series had a complete course of megavoltage radio-
therapy. The remainder included patients who had dis-
tant metastases or extensive loco-regional infiltration:
in these conditions, radical treatment was not feasible
technically. Indeed, 240 (5.0%) of the patients were
too ill for any form of local irradiation to be performed.
Adjunctive chemotherapy was given to 416 (8.7%)
of the patients who were at an advanced stage of dis-
ease or who had a poor response to primary radio-
therapy. Various cytotoxic drugs (including cisplatin,
5-fluorouracil, cyclophosphamide, methotrexate, and
bleomycin) had been given. Neck dissection was done
in 18 patients who had residual or recurrent lymph
nodes, and lobectomy was performed in seven patients
who had solitary lung metastasis.
Statistical methods
Five different aspects were studied: (1) The presenting
symptoms and signs were summarised, and the pat-
tern of the symptom duration was studied. (2) Possi-
ble host factors affecting the symptom duration were
analysed with contingency tables and the Chi squared
test. (3) The independent significance of the symptom
duration on the presenting stage was assessed; patients
were grouped into early (stages I-II) and advanced
(stages III-V) stage categories. Logistic regression was
applied to test the association, following adjustment
for other covariates. (4) The correlation between symp-
tom duration and subsequent radiotherapy was ana-
lysed with contingency tables and Chi squared test.
(5) The effect of symptom duration on the final out-
come in terms of disease-specific deaths was studied.
Actuarial incidences (measured from the date of diag-
nosis) were calculated by the Kaplan-Meier method,12
Results are based on a series of 5020 patients with undifferentiated or nonkeratinising carcinoma of the nasopharynx
treated at the Queen Elizabeth Hospital during 1976-1985
Fig 1. Actuarial disease-specific survival for patients with different presenting stage categories
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and the differences were compared using the log-rank
test.13 The independent significance of the symptom-
duration was further analysed by the Cox regression
model.14
Results
Presenting features and duration
While 3903 (81.9%) of the patients presented with
multiple symptoms, 851 (17.8%) reported one symp-
tom; the remainder were asymptomatic. Forty percent
of patients had no external signs. The frequency of
different presenting symptoms and signs are listed in
Tables 1 and 2, respectively. The painless enlargement
of the upper cervical lymph node(s) was the most com-
mon presenting feature. Gross lymphatic spread at the
time of diagnosis was present in 3550 (74.5%) of the
patients, and of these 1788 (50.4%) had bilateral in-
volvement. Of the whole series, 2585 (54.2%) had no
physical signs other than nodal (unilateral or bilateral)
enlargement.
Approximately three quarters of the patients com-
plained of nasal symptoms; however, there was no
obvious abnormality found from a general physical ex-
amination. Approximately 20% of patients presented
with otological symptoms but by the time of diagnosis
62.4% were affected and 5.0% had a gross impairment
of hearing. Headache and/or symptoms of cranial nerve
dysfunction were rarely the first reported complaint,
but 20.0% of patients eventually developed cranial or
cervical sympathetic nerve palsy. Figure 2 shows the
frequency of nerve involvement; the fifth and the sixth
nerve were the most frequently involved (frequencies
of 12.5% and 10.5% respectively).
The mean symptom duration before the establish-
ment of a diagnosis was 8 months, with a wide range
of 1 to 36 months for 95% of the series (Fig 3). For
convenience, patients were divided into two groups for
further analysis: a short symptom duration group of
2354 (49%) patients who had no symptoms, or had
had symptoms for less than 6 months, and a long symp-
Table 1. Presenting symptoms and their frequencies (n=4768)
Symptom Number of patients
Only symptom First symptom* Total No. presenting
with symptom
  No. (%) No. (%) No. (%)
Neck mass 37 (0.8) 1777 (37.3) 3612 (75.8)
Nasal (discharge, bleeding, obstruction) 65 (1.4) 1687 (35.4) 3501 (73.4)
Aural (tinnitus, impairment of hearing) 54 (1.1) 912 (19.1) 2975 (62.4)
Headache 13 (0.3) 175 (3.7) 1657 (34.8)
Ophthalmic (diplopia, squint) 4 (0.1)  48 (1.0) 512 (10.7)
Facial numbness 3 (0.1)  22 (0.5)  361 (7.6)
Weight loss 0  1  329 (6.9)
Trismus 2  2  141 (3.0)
Slurring of speech 0  3 (0.1)  114 (2.4)
Others due to metastatic deposits 0  12 (0.3)  57 (1.2)
Skin lesions due to dermatomyositis 4 (0.1)  6 (0.1)  42 (0.9)
*In patients presenting with multiple symptoms
Table 2. Physical signs at the time of diagnosis and their frequencies (n=4768)
Physical sign Only sign One of multiple signs Total No. at diagnosis
No. (%) No. (%) No. (%)
Enlarged neck node(s)  2594 (54.4)  956 (20.1) 3550 (74.5)
Cranial nerve palsy  203 (4.3)  749 (15.7) 952 (20.0)
Deafness  51 (1.1)  186 (3.9)  237 (5.0)
Trismus  3 (0.1)  70 (1.5)  73 (1.5)
Proptosis  1  15 (0.3)  16 (0.3)
Metastases  0  122 (2.6)  122 (2.6)
Dermatomyositis  17 (0.4)  17 (0.4)  34 (0.7)
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tom duration group of 2414 (51%) patients who had
had symptoms for 6 months or longer. These groups
are hereafter referred to as early and late presenters,
respectively.
Factors affecting duration of symptoms
A larger proportion of the male patients had had symp-
toms for 6 months or less when compared with the
females (51% versus 46%; P=0.003). There was also
a trend towards an earlier presentation in the younger
patients. The proportion of early presenters in patients
aged below 40, 40 to 60, and above 60 years were 52%,
49% and 47%, respectively; the difference was just
short of statistical significance (P=0.066). Patients
treated in the latter half of the study period presented
significantly earlier: the proportion of early presenters
was 54% during the years 1981 to 1985 compared with
44% during the years 1976 to 1980 (P<0.001). The
mean symptom duration was also shorter (7.4 months
compared with 8.8 months).
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Fig 2. Involvement of different cranial nerves at diagnosis (n=4768)
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Factors affecting presenting stage and radiotherapy
Figure 4 shows the different distributions of stage cate-
gory for the two groups. While 58% of stage I cases
had had symptoms for less than 6 months, only 39%
of stage V patients were early presenters (P<0.001).
Logistic regression (incorporating age, sex, and treat-
ment era as covariates) showed that symptom dura-
tion was a significant factor associated with stage
category (Table 3); the odds ratio for presenting with
Stage I-II disease was 0.981 per month’s delay in diag-
nosis (P<0.001). Consequently, the pattern of radio-
therapy was different in the two groups (P=0.001). A
lower proportion of late presenters had a full course of
radical megavoltage radiotherapy (89% versus 92%),
but more of them were too advanced for any radio-
therapy attempt (6% versus 4%).
Impact on final outcome
The 10-year actuarial disease-specific survival was sig-
nificantly higher in early presenters (48% versus 42%;
P<0.001) [Fig 5]. Univariate analysis showed that the
symptom duration was a significant prognostic factor
that affected the risk of disease-specific deaths: the
hazard ratio was 1.011 per month;  95% confidence
interval = 1.007-1.016 per month (P<0.001). Multivariate
analysis showed that the most significant prognostic
factors were age, sex, treatment era, presenting stage
and completeness of radiotherapy (Table 4). When ad-
justed for these factors, the impact of symptom duration
failed to show statistical significance (P=0.14).
Discussion
The presenting stage is one of the most important prog-
nostic factors affecting the survival for patients with
NPC (Fig 1). There are marked differences in the inci-
dence of treatment failure and there is often a need for
salvage/supportive treatment. The impacts due to the
subsequent loss of working life and the cost of health
care are substantial.
One of the significant factors associated with the pre-
senting stage for undifferentiated or non-keratinising
carcinoma (which accounted for 99.7% of the NPC
cases in Hong Kong in this study) was the duration of
symptom(s) before the establishment of the diagnosis
(Fig 4 and Table 3). Logistic regression showed that
the odds of presenting with Stage I-II diseases de-
creased by 2% for each month’s delay in diagnosis.
An untreated tumour leads to extensive damage and
an increased chance of dissemination; it was thus not
surprising that a larger proportion of the late present-
ers was too ill for any local treatment (6% compared
Fig 4. Relationship between symptom duration and presenting stage category
Table 3. Logistic regression analysis of the association between stage category (I-II versus III-V) and
various factors
Factor Odds ratio 95% confidence interval P value
Age (years) 0.991 0.986-0.997 0.002
Sex (male, female) 0.819 0.760-0.883 <0.001
Treatment era (1981-85, 1976-80) 0.971 0.906-1.040 0.401
Symptom duration (months) 0.981 0.972-0.990 <0.001
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with 4% for the early presenters). In addition, a smaller
proportion of the late presenters received a full course
of radical radiotherapy by megavoltage photons (89%
versus 92%). The adverse effect on these two most
important prognostic factors was reflected by the
significantly lower 10-year actuarial disease-specific
survival among the late presenters (42% versus
48%; P<0.001) [Fig 5]. The symptom duration per se,
however, was not an independent prognostic factor
according to the analysis by the Cox regression model
(P=0.14) [Table 4].
More than half of the patients treated during this
study had had symptoms for 6 months or longer be-
fore referral to radiotherapy departments (Fig. 3); there
was nevertheless a sign of improvement thereafter.
Despite there being a significantly larger proportion
of early presenters in the latter era studied (54%
during 1981 to 1985 versus 44% during 1976 to 1980;
P<0.001), the mean duration of delay (7.4 months) be-
fore the establishment of the diagnosis is still undesir-
ably long. Greater public awareness is obviously
needed. Awareness among the female population and
the elderly are especially inadequate at present. More
concerted efforts in educating the public on common
presenting features and the importance of early pres-
entation are vital. In addition, fellow colleagues should
be more alert in considering this differential diagnosis
to avoid undue delay. The presenting symptoms and
signs which are outlined in Tables 1 and 2 should be
duly recognised.
A thorough examination of the nasopharynx, and a
serological test (serum IgA against the viral capsid
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*Early and late presenters reported symptom duration of less than 6 months, and 6 months or longer, respectively
Fig 5. Actuarial disease-specific survival for early and late presenters*
Table 4. Multivariate analysis of prognostic factors and disease-specific deaths using the Cox regression
model
Prognostic factor Disease-specific deaths
Hazard ratio 95% confidence interval P value
Age (years) 1.012 1.009-1.016 <0.001
Sex (male, female) 0.880 0.838-0.924 <0.001
Treatment era (1981-85, 1976-80) 1.110 1.064-1.158 <0.001
Stage (I, II, III, IV, V) <0.001
Radiotherapy (nil, incomplete, radical) <0.001
Symptom duration (months) 1.003 0.999-1.008   0.142
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antigen of the Epstein-Barr virus) should be offered to
all patients with a persistent enlargement of the upper
cervical lymph nodes, nasal symptoms, otological
problems, headache or cranial nerve dysfunction. The
latter two features are frequently mistaken as tension
headache, temporal arteritis or diabetic neuropathy. A
frustrating consequence of misdiagnosis is that patients
with classic fifth and sixth nerve palsy are sometimes
subjected to various fruitless investigations, such as
computed tomography of the brain, which miss the
detection of a nasopharyngeal lesion at the edges.
The association of otological symptoms with NPC
is inadequately recognised. While only 20% of patients
recorded this as the presenting complaint, 62% had
tinnitus, serous otitis media and/or an impairment of
hearing by the time of diagnosis. If patients have a
more detailed otological assessment (including a pure
tone audiogram), the incidence of abnormality would
likely be even higher. More recent studies suggested
that the incidence of otitis media could be as high as
40%.15 It should also be noted that dermatomyositis is
associated with prevalent malignancies,16 and that this
was the only symptom in 0.2% of the present series.
The interval from detection of NPC could range from
1 to 1014 months (mean, 207 months). Hence, all
patients with dermatomyositis should be thoroughly
investigated and regularly followed up even if no
apparent malignancy is found.
The importance of the early detection and diagno-
sis cannot be overemphasised. By improving the
knowledge and awareness of this leading malignancy,
any further delay in presentation will be minimised.
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